Alexy Inciarte

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8089078/alexy-inciarte-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 644 10 25 g-index

46 1,125 4.9 3.56 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
38	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57) <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab595	1	0
37	Increasing emergency department admissions for chemsex-related intoxications in Barcelona, Spain, among people living with HIV: an observational study from 2018 to 2020 <i>BMC Public Health</i> , 2022 , 22, 346	4.1	1
36	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19 <i>Scientific Reports</i> , 2022 , 12, 5250	4.9	5
35	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients <i>Infection</i> , 2022 , 1	5.8	0
34	Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. <i>Trials</i> , 2021 , 22, 851	2.8	O
33	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. <i>Lancet HIV,the</i> , 2021 , 8, e701-e710	7.8	10
32	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021 , 1	6.2	1
31	Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 164-168	10.5	19
30	Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1253-1266	6.2	2
29	Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. <i>Revista Espanola De Quimioterapia</i> , 2021 , 34, 238-244	1.6	5
28	Overview of SARS-CoV-2 infection in adults living with HIV. <i>Lancet HIV,the</i> , 2021 , 8, e294-e305	7.8	46
27	Experience with the use of siltuximab in patients with SARS-CoV-2 infection. <i>Revista Espanola De Quimioterapia</i> , 2021 , 34, 337-341	1.6	4
26	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 83-88	9.5	280
25	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , 2021 , 22, 218-224	2.7	0
24	Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2988-2992	5.1	O
23	Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin. <i>Clinical Infectious Diseases</i> , 2021 , 73, 614-620	11.6	1
22	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. <i>Thorax</i> , 2021 , 76, 920-929	7.3	12

21	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. <i>BMJ Open</i> , 2021 , 11, e040775	3	2
20	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3296-3302	5.1	4
19	Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon №a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. <i>Frontiers in Immunology</i> , 2021 , 12, 767370	8.4	0
18	Smell and Taste Dysfunction in COVID-19 Is Associated With Younger Age in Ambulatory Settings: A Multicenter Cross-Sectional Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020 , 30, 346-357	2.3	51
17	About "Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients". <i>Enfermedades Infecciosas Y Microbiolog</i> Claica, 2020 , 38, 299-300	0.9	2
16	Post-exposure prophylaxis for HIV infection in sexual assault victims. HIV Medicine, 2020, 21, 43-52	2.7	3
15	High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. <i>EBioMedicine</i> , 2020 , 62, 103077	8.8	5
14	Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. <i>Aids</i> , 2020 , 34, 1775-1780	3.5	47
13	A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine. Aids, 2019, 33, 1891	1 -318 96	7
12	Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2019 , 19, 1030	4	7
12		5.1	7
	BMC Infectious Diseases, 2019, 19, 1030 Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2018,		
11	BMC Infectious Diseases, 2019, 19, 1030 Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1965-1971 IL7RA polymorphisms are not associated with AIDS progression. European Journal of Clinical	5.1	32
11	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1965-1971 IL7RA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017 , 47, 719-727 Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial</i>	5.1 4.6	32
11 10 9	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1965-1971 IL7RA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017 , 47, 719-727 Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2857-2861 A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of</i>	5.14.65.1	32 2 6
11 10 9 8	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1965-1971 ILTRA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017 , 47, 719-727 Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2857-2861 A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1982-6 A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of</i>	5.14.65.1	3 ² 2 6
11 10 9 8	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1965-1971 ILTRA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017, 47, 719-727 Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2857-2861 A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1982-6 A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1987-93 Factors Associated with Hospitalization among Emergency Department Patients Referred for Quick	5.1 4.6 5.1 5.1	32 2 6 6 8

3	Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. <i>Aids</i> , 2015 , 29, 675-81	3.5	29
2	A case of Japanese encephalitis in a 20 year-old Spanish sportsman, February 2013. <i>Eurosurveillance</i> , 2013 , 18, 20573	19.8	8
1	Vulnerability Conditions in a Cohort of Men Who Have Sex with Men Who Engage in Chemsex in Barcelona City: a Cross-Sectional Study. <i>Sexuality Research and Social Policy</i> ,1	2.1	0